Tempest Therapeutics, Inc.
TPST
$6.87
$0.385.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.55M | 13.70M | 13.08M | 12.39M | 11.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.03M | 35.62M | 31.66M | 29.55M | 29.16M |
| Operating Income | -42.03M | -35.62M | -31.66M | -29.55M | -29.16M |
| Income Before Tax | -41.84M | -35.52M | -31.75M | -29.76M | -29.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.84 | -35.52 | -31.75 | -29.76 | -29.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.84M | -35.52M | -31.75M | -29.76M | -29.49M |
| EBIT | -42.03M | -35.62M | -31.66M | -29.55M | -29.16M |
| EBITDA | -41.64M | -35.20M | -31.25M | -29.21M | -28.78M |
| EPS Basic | -19.84 | -20.45 | -21.38 | -22.85 | -25.44 |
| Normalized Basic EPS | -12.40 | -12.78 | -13.36 | -14.28 | -15.90 |
| EPS Diluted | -19.84 | -20.45 | -21.38 | -22.85 | -25.44 |
| Normalized Diluted EPS | -12.40 | -12.78 | -13.36 | -14.28 | -15.90 |
| Average Basic Shares Outstanding | 8.58M | 6.93M | 6.03M | 5.38M | 4.73M |
| Average Diluted Shares Outstanding | 8.58M | 6.93M | 6.03M | 5.38M | 4.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |